公开(公告)号：US10428054B2

公开(公告)日：2019-10-01

申请号：US15851434

申请日：2017-12-21

Applicant: CHDI Foundation, Inc.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Mitchell ,  Naomi Went

IPC: A61K31/517 ,  A61K31/495 ,  A61K31/47 ,  A61K31/425 ,  A61K31/42 ,  A61K31/415 ,  A61K31/34 ,  C07D413/12 ,  C07D215/18 ,  C07D319/18 ,  C07D333/06 ,  C07D241/42 ,  C07D277/24 ,  C07D277/64 ,  C07D213/46 ,  C07D307/79 ,  C07D209/08 ,  C07D217/02 ,  C07D231/56 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D261/20 ,  C07D263/56 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12 ,  A61K31/428 ,  A61K31/416 ,  A61K31/343 ,  A61K31/423 ,  A61K31/4184 ,  A61K31/502

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US09884853B2

公开(公告)日：2018-02-06

申请号：US14392304

申请日：2014-09-23

Applicant: CHDI Foundation, Inc.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Mitchell ,  Naomi Went

IPC: C07D413/00 ,  C07D263/00 ,  C07D307/00 ,  C07D277/60 ,  C07D231/56 ,  C07D209/04 ,  C07D237/26 ,  C07D239/72 ,  C07D217/00 ,  C07D215/00 ,  C07D413/12 ,  C07D215/18 ,  C07D319/18 ,  C07D333/06 ,  C07D241/42 ,  C07D277/24 ,  C07D277/64 ,  C07D213/46 ,  C07D307/79 ,  C07D209/08 ,  C07D217/02 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D261/20 ,  C07D263/56 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12

CPC classification number: C07D413/12 ,  C07D209/08 ,  C07D213/46 ,  C07D215/18 ,  C07D217/02 ,  C07D231/56 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D241/42 ,  C07D261/20 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D307/79 ,  C07D319/18 ,  C07D333/06 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US09822058B2

公开(公告)日：2017-11-21

申请号：US14390190

申请日：2013-03-13

Applicant: CHDI FOUNDATION, INC.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Leonard Mitchell ,  Peter Johnson ,  Naomi Went

IPC: C07C62/38 ,  C07D307/94 ,  C07D309/10 ,  C07D215/18 ,  C07D311/58 ,  C07D317/46 ,  C07D317/60 ,  C07D319/18 ,  C07D233/64 ,  C07D235/26 ,  C07D403/10 ,  C07D405/08 ,  C07D405/10 ,  C07D405/12 ,  C07C317/44 ,  C07D413/08 ,  C07D413/10 ,  C07C323/62 ,  C07C229/22 ,  C07C229/46 ,  C07C229/48 ,  C07D257/04 ,  C07D203/08 ,  C07D263/58 ,  C07C235/82 ,  C07D207/08 ,  C07D271/07 ,  C07D207/337 ,  C07D295/155 ,  C07D305/06 ,  C07D305/08 ,  C07D307/54 ,  C07D307/80 ,  C07C69/757 ,  C07D203/10 ,  C07D307/79 ,  C07D413/12 ,  C07H15/20

CPC classification number: C07C62/38 ,  C07C69/757 ,  C07C229/22 ,  C07C229/46 ,  C07C229/48 ,  C07C235/82 ,  C07C317/44 ,  C07C323/62 ,  C07C2601/02 ,  C07C2602/50 ,  C07D203/08 ,  C07D203/10 ,  C07D207/08 ,  C07D207/337 ,  C07D215/18 ,  C07D233/64 ,  C07D235/26 ,  C07D257/04 ,  C07D263/58 ,  C07D271/07 ,  C07D295/155 ,  C07D305/06 ,  C07D305/08 ,  C07D307/54 ,  C07D307/79 ,  C07D307/80 ,  C07D307/94 ,  C07D309/10 ,  C07D311/58 ,  C07D317/46 ,  C07D317/60 ,  C07D319/18 ,  C07D403/10 ,  C07D405/08 ,  C07D405/10 ,  C07D405/12 ,  C07D413/08 ,  C07D413/10 ,  C07D413/12 ,  C07H15/20

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.